NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/05/2023
Back to search
Official data from USPTO
THERAMEX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
18
Latest update
12/05/2023
Trademark type
Combined
Nice classes
5
Filing date
09/08/2022
Registration date
12/05/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/05/2023
Last transaction
12/05/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
3
Owner type
99
Owner location
Belgravia, London, GB
Examiner
BERNS, LEE ANNE
Law office
M90
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the term 'THERAMEX' to the right of a lady figure.
Holders and representatives
Holders
Theramex HQ UK Limited
Representatives
Leigh Ann Lindquist SUGHRUE MION, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Anti-fungal pharmaceutical preparations; Contraceptive preparations; contraceptive sponges; chemical contraceptives; oral contraceptives; Dermatological pharmaceutical preparations; Diagnostic preparations for medical purposes; Pharmaceutical preparations and substances for use in relation to women's healthmenopauseosteoporosisuterine fibroidsendometriosisadenomyosismenstrual bleeding disordersfertilityinfertilityassisted reproductive technologyIVF; Pharmaceutical preparations and substances containing steroids; Pharmaceutical preparations and substances containing hormones; Pharmaceutical preparations and substances in the nature of hormone replacement therapy; pharmaceutical preparations and substances for use in relation to reproductive healthcontraceptionmenstrual bleeding disordersfertilityinfertilityfertility enhancement preparationsassisted reproductive technologyIVFmiscarriage; pharmaceutical preparations and substances for use in relation to contraception; pharmaceutical preparations and substances for use in relation to conceptioncontraceptionmenstrual bleeding disordersfertilityinfertilityfertility enhancement preparationsassisted reproductive technologyIVFmiscarriage; pharmaceutical preparations and substances for use in relation to fertility; fertility enhancement preparations; pharmaceutical preparations and substances for use in relation to the treatment of infertility; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in gynaecology; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for use in dermatology; Pharmaceutical preparations for the treatment of menopause; Pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; Pharmaceutical preparations and substances for the treatment of osteoporosis; Pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; Pharmaceutical preparations and substances for the treatment of cartilage disorders; Pharmaceutical preparations and substances for the treatment of bone disorders; Pharmaceutical preparations and substances for the treatment of bone loss; Pharmaceutical preparations and substances for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of calcium deficiency; Pharmaceutical preparations and substances being calcium regulators; Pharmaceutical preparations and substances for the treatment of Paget's disease; Phosphates for pharmaceutical purposes; Self-injectors sold filled with pharmaceutical preparations for the treatment of infertility for subcutaneous injectionosteoporosis; Vitamin supplements; mineral supplements; calcium supplements; all the above being for human use and none being for dental use or for use in relation to oral hygiene
Publications
History of USPTO decisions and trademark events.
18 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/05/2023
ISPO
WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST
09/21/2023
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
09/20/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/19/2023
PUBO
PUBLISHED FOR OPPOSITION
09/19/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/30/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/14/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/11/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/11/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/11/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/06/2023
GNRT
NON-FINAL ACTION E-MAILED
07/06/2023
CNRT
NON-FINAL ACTION WRITTEN
07/06/2023
DOCK
ASSIGNED TO EXAMINER
06/22/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
09/27/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/26/2022
NWAP
NEW APPLICATION ENTERED
09/12/2022
Continuous trademark protection
Get notified about every new filing that threatens THERAMEX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.